Jul 2, 2020 - Health

Regeneron and Sanofi stop trial for coronavirus treatment

A patient lays in a hospital bed surrounded by a ventilator and other medical supplies.
Kevzara was tested on critically ill coronavirus patients. Photo: Robert Nickelsberg/Getty Images

Regeneron Pharmaceuticals and Sanofi have shut down the late-stage clinical trial that was testing whether their existing arthritis drug, Kevzara, could improve the condition of COVID-19 patients who were on ventilators.

The bottom line: Kevzara fared no better than a placebo, as it failed to help COVID-19 patients recover or prevent death. Remdesivir remains as the only treatment that has shown any kind of benefit for sick coronavirus patients, although dexamethasone appears to hold the most promise.

Go deeper